Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) established initial surge of 4.54% at $44.43, as the Stock market unbolted on Wednesday, before settling in for the price of $42.5 at the close. Taking a more long-term approach, CRNX posted a 52-week range of $24.10-$62.53.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -12.11%. Meanwhile, its Annual Earning per share during the time was -12.11%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -29.45%. This publicly-traded company’s shares outstanding now amounts to $94.13 million, simultaneously with a float of $87.11 million. The organization now has a market capitalization sitting at $4.18 billion. At the time of writing, stock’s 50-day Moving Average stood at $33.65, while the 200-day Moving Average is $34.38.
Crinetics Pharmaceuticals Inc (CRNX) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Crinetics Pharmaceuticals Inc industry. Crinetics Pharmaceuticals Inc’s current insider ownership accounts for 7.53%, in contrast to 107.74% institutional ownership. According to the most recent insider trade that took place on Oct 01 ’25, this organization’s Chief Med and Dev Officer sold 5,000 shares at the rate of 41.81, making the entire transaction reach 209,050 in total value, affecting insider ownership by 66,270.
Crinetics Pharmaceuticals Inc (CRNX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.
Crinetics Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -29.45% and is forecasted to reach -5.01 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -1.76% through the next 5 years, which can be compared against the -12.11% growth it accomplished over the previous five years trading on the market.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Let’s observe the current performance indicators for Crinetics Pharmaceuticals Inc (CRNX). It’s Quick Ratio in the last reported quarter now stands at 17.80. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3010.24.
In the same vein, CRNX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.11, a figure that is expected to reach -1.25 in the next quarter, and analysts are predicting that it will be -5.01 at the market close of one year from today.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Now, what If we examine the latest scores posted by [Crinetics Pharmaceuticals Inc, CRNX]. During the last 5-days, its volume was better the volume of 1.09 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 59.10% While, its Average True Range was 71.39.
Raw Stochastic average of Crinetics Pharmaceuticals Inc (CRNX) in the period of the previous 100 days is set at 86.19%, which indicates a major rise in contrast to 78.92% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 2.37 that was higher than 1.45 volatility it exhibited in the past 100-days period.
